These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

657 related articles for article (PubMed ID: 34731863)

  • 1. Early Changes in Alpha-Fetoprotein Are a Useful Predictor of Efficacy of Atezolizumab plus Bevacizumab Treatment in Patients with Advanced Hepatocellular Carcinoma.
    Kuzuya T; Kawabe N; Hashimoto S; Miyahara R; Sawaki A; Nakano T; Nakaoka K; Tanaka H; Miyachi Y; Mii A; Kamejima S; Takahara T; Kato Y; Sugioka A; Hirooka Y
    Oncology; 2022; 100(1):12-21. PubMed ID: 34731863
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Early Changes in Alpha-Fetoprotein and Des-γ-Carboxy Prothrombin Are Useful Predictors of Antitumor Response to Durvalumab Plus Tremelimumab Therapy for Advanced Hepatocellular Carcinoma.
    Kuzuya T; Kawabe N; Muto H; Wada Y; Komura G; Nakano T; Tanaka H; Nakaoka K; Ohno E; Funasaka K; Nagasaka M; Miyahara R; Hirooka Y
    Curr Oncol; 2024 Jul; 31(8):4225-4240. PubMed ID: 39195298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alpha-fetoprotein and des-gamma-carboxy prothrombin can predict the objective response of patients with hepatocellular carcinoma receiving durvalumab plus tremelimumab therapy.
    Saeki I; Shimose S; Tomonari T; Ito T; Tani J; Takeuchi Y; Yoshioka N; Naito T; Takeuchi M; Kakizaki S; Hatanaka T; Sasaki K; Yasunaka T; Sakata M; Iwamoto H; Itano S; Shirono T; Tanabe N; Yamamoto T; Kanayama Y; Naganuma A; Nishina S; Otsuka M; Kobara H; Kawashima H; Takayama T; Kawaguchi T; Yamasaki T; Takami T;
    PLoS One; 2024; 19(9):e0311084. PubMed ID: 39321197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
    Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
    Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma.
    Komatsu S; Yano Y; Fujishima Y; Ishida J; Kido M; Kuramitsu K; Yamamoto A; Goto T; Yanagimoto H; Toyama H; Ueda Y; Kodama Y; Fukumoto T
    Anticancer Res; 2022 Mar; 42(3):1403-1412. PubMed ID: 35220233
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice.
    Hayakawa Y; Tsuchiya K; Kurosaki M; Yasui Y; Kaneko S; Tanaka Y; Ishido S; Inada K; Kirino S; Yamashita K; Nobusawa T; Matsumoto H; Kakegawa T; Higuchi M; Takaura K; Tanaka S; Maeyashiki C; Tamaki N; Nakanishi H; Itakura J; Takahashi Y; Asahina Y; Okamoto R; Izumi N
    Invest New Drugs; 2022 Apr; 40(2):392-402. PubMed ID: 34586531
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of early response to hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma using the combination of response evaluation criteria in solid tumors and tumor markers.
    Miyaki D; Kawaoka T; Aikata H; Kan H; Fujino H; Fukuhara T; Kobayashi T; Naeshiro N; Honda Y; Tsuge M; Hiramatsu A; Imamura M; Hyogo H; Kawakami Y; Yoshimatsu R; Yamagami T; Awai K; Chayama K
    J Gastroenterol Hepatol; 2015 Apr; 30(4):726-32. PubMed ID: 25311578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
    Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
    Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early Decreases in α-Fetoprotein and Des-γ-carboxy Prothrombin Predict the Antitumor Effects of Hepatic Transarterial Infusion Chemotherapy with Cisplatin (CDDP) Powder in Patients with Advanced Hepatocellular Carcinoma.
    Hatanaka T; Kakizaki S; Shimada Y; Takizawa D; Katakai K; Yamazaki Y; Sato K; Kusano M; Yamada M
    Intern Med; 2016; 55(16):2163-71. PubMed ID: 27522991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.
    Meguro M; Mizuguchi T; Nishidate T; Okita K; Ishii M; Ota S; Ueki T; Akizuki E; Hirata K
    World J Gastroenterol; 2015 Apr; 21(16):4933-45. PubMed ID: 25945007
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Early decrease in α-fetoprotein, but not des-γ-carboxy prothrombin, predicts sorafenib efficacy in patients with advanced hepatocellular carcinoma.
    Kuzuya T; Asahina Y; Tsuchiya K; Tanaka K; Suzuki Y; Hoshioka T; Tamaki S; Kato T; Yasui Y; Hosokawa T; Ueda K; Nakanishi H; Itakura J; Takahashi Y; Kurosaki M; Izumi N
    Oncology; 2011; 81(3-4):251-8. PubMed ID: 22116493
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma: Early clinical experience.
    Hiraoka A; Kumada T; Tada T; Hirooka M; Kariyama K; Tani J; Atsukawa M; Takaguchi K; Itobayashi E; Fukunishi S; Tsuji K; Ishikawa T; Tajiri K; Ochi H; Yasuda S; Toyoda H; Ogawa C; Nishimura T; Hatanaka T; Ohama H; Nouso K; Morishita A; Tsutsui A; Nagano T; Itokawa N; Okubo T; Arai T; Imai M; Koizumi Y; Nakamura S; Joko K; Iijima H; Hiasa Y; Kudo M;
    Cancer Rep (Hoboken); 2022 Feb; 5(2):e1464. PubMed ID: 34114752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinicopathologic features of patients with hepatocellular carcinoma seropositive for alpha-fetoprotein-L3 and seronegative for des-gamma-carboxy prothrombin in comparison with those seropositive for des-gamma-carboxy prothrombin alone.
    Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Yamamoto M; Takasaki K; Nakano M
    J Gastroenterol Hepatol; 2002 Jul; 17(7):772-8. PubMed ID: 12121507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A new therapeutic assessment score for advanced hepatocellular carcinoma patients receiving hepatic arterial infusion chemotherapy.
    Saeki I; Yamasaki T; Tanabe N; Iwamoto T; Matsumoto T; Urata Y; Hidaka I; Ishikawa T; Takami T; Yamamoto N; Uchida K; Terai S; Sakaida I
    PLoS One; 2015; 10(5):e0126649. PubMed ID: 25992784
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Evaluation of the mRECIST and α-fetoprotein ratio for stratification of the prognosis of advanced-hepatocellular-carcinoma patients treated with sorafenib.
    Kawaoka T; Aikata H; Murakami E; Nakahara T; Naeshiro N; Tanaka M; Honda Y; Miyaki D; Nagaoki Y; Takaki S; Hiramatsu A; Waki K; Takahashi S; Chayama K
    Oncology; 2012; 83(4):192-200. PubMed ID: 22890083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma.
    Su D; Wu B; Shi L
    JAMA Netw Open; 2021 Feb; 4(2):e210037. PubMed ID: 33625508
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Early increase in α-fetoprotein for predicting unfavorable clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib.
    Nakazawa T; Hidaka H; Takada J; Okuwaki Y; Tanaka Y; Watanabe M; Shibuya A; Minamino T; Kokubu S; Koizumi W
    Eur J Gastroenterol Hepatol; 2013 Jun; 25(6):683-9. PubMed ID: 23395995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of Tumor Response Using Alpha-fetoprotein and Des-gamma-carboxy Prothrombin in Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization.
    Cerban R; Ester C; Iacob S; Paslaru L; Dumitru R; Grasu M; Constantin G; Popescu I; Gheorghe L
    Chirurgia (Bucur); 2018; 113(4):524-533. PubMed ID: 30183583
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The tumor marker score is an independent predictor of survival in patients with recurrent hepatocellular carcinoma.
    Okamura Y; Ashida R; Ito T; Sugiura T; Mori K; Uesaka K
    Surg Today; 2015 Dec; 45(12):1513-20. PubMed ID: 25527455
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early on-treatment predictions of clinical outcomes using alpha-fetoprotein and des-gamma-carboxy prothrombin responses in patients with advanced hepatocellular carcinoma.
    Lee MH; Kim SU; Kim DY; Ahn SH; Choi EH; Lee KH; Lee DY; Seong J; Han KH; Chon CY; Park JY
    J Gastroenterol Hepatol; 2012 Feb; 27(2):313-22. PubMed ID: 21793906
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.